Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + sEphB4-HSA in Metastatic Urothelial Carcinoma
NCT04486781Phase 2Recruiting
- Sponsor
- VasGene Therapeutics, Inc.
- Start
- Aug 2020
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sephb4-hsa in urothelial carcinoma (UC), sponsored by VasGene Therapeutics, Inc. Primary endpoint: Overall Response Rate at 60 months. Started Aug 2020; status: recruiting.
02
Drugs
sephb4-hsa
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04486781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486781.